No beneficial effects seen for cyclosporine A in reperfused MI

January 28, 2016

(HealthDay)—A single intravenous cyclosporine A (CsA) bolus just before primary percutaneous coronary intervention has no beneficial effects on ST-segment resolution in reperfused myocardial infarction (MI), according to a study published in the Feb. 2 issue of the Journal of the American College of Cardiology.

Filippo Ottani, M.D., from the Ospedale GB Morgagni in Forli, Italy, and colleagues examined the effect of CsA on ST-segment resolution. Patients (age 63 ± 12 years) from 31 cardiac care units, with large ST-segment elevation MI and Thrombolysis In Myocardial Infarction flow grade 0 to 1 in the infarct-related artery, were randomized to 2.5 mg/kg intravenous CsA (207 ) or control (203 patients) before .

The researcher found that 52.0 percent of CsA patients and 49.0 percent of controls had ST-segment resolution ≥70 percent (P = 0.55). On day four, the median high-sensitivity cardiac troponin T (hs-cTnT) was 2,160 and 2,063 ng/L in the CsA and control group, respectively (P = 0.85). There was no between-group difference in left ventricular (LV) ejection fraction on day four and at six months. The site of infarct did not affect CsA efficacy. No acute allergic reactions were seen, or nonsignificant excesses of six-month mortality (5.7 versus 3.2 percent; P = 0.17) or cardiogenic shock (2.4 versus 1.5 percent; P = 0.33).

"In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial, a single intravenous CsA bolus just before primary percutaneous coronary intervention had no effect on ST-segment resolution or hs-cTnT, and did not improve clinical outcomes or LV remodeling up to six months," the authors write.

One author disclosed financial ties to the pharmaceutical and medical device industries. The CYCLE trial was partially funded by Novartis Italy. Reagents for measuring hs-cTnT were provided by Roche Diagnostics.

Explore further: Cyclosporine does not improve outcomes after PCI

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Cyclosporine does not improve outcomes after PCI

August 30, 2015
The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation ...

Pharmacoinvasive STEMI strategy best for smokers, nonsmokers

October 27, 2014
(HealthDay)—For patients with ST-segment elevation myocardial infarction, a pharmacoinvasive strategy after fibrinolysis is beneficial for smokers and nonsmokers, according to a study published in the Oct. 1 issue of The ...

White blood cell count predicts infarct size in STEMI

December 19, 2013
(HealthDay)—For patients with anterior wall ST-segment elevated myocardial infarction (STEMI), elevated white blood cell count (WBCc) on presentation is associated with increased infarct size, according to a study published ...

Cardiac prognosis bright for STEMI survivors post-PCI

November 11, 2014
(HealthDay)—Patients who survive the first month after an ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) have

Nonalcoholic fatty liver disease predicts MACE in STEMI

November 30, 2015
(HealthDay)—For patients without diabetes with ST-segment myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), nonalcoholic fatty liver disease (FLD) independently predicts impaired ...

Early invasive strategy no benefit 10 years after NSTE-ACS

July 29, 2015
(HealthDay)—For patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), routine early invasive strategy (coronary arteriography and myocardial revascularization, as clinically indicated) is not associated ...

Recommended for you

Some cancer therapies may provide a new way to treat high blood pressure

November 20, 2017
Drugs designed to halt cancer growth may offer a new way to control high blood pressure (hypertension), say Georgetown University Medical Center investigators. The finding could offer a real advance in hypertension treatment ...

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017
Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.